# NG Bio

NG Bio is a Private Equity based in London, United Kingdom.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** 35 Ballards Lane, London, N3 1XW, United Kingdom
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** ngbio.co.uk
- **LinkedIn:** linkedin.com/company/ng-bio
- **Wikidata:** Q30271864

## Regulatory record

- **Reports private funds:** No

## About

NG Bio is an early-stage investor and venture builder unlocking the power of the immune system. From autoimmunity to women's health, they target immunology as both the underlying cause and the definitive solution. They work on breakthrough cures for chronic diseases.

## Sectors

- Biotech
- Healthcare Services

## People

- Mohammad Khobreh — Co-Founder
- Jason Goldstein — Co-Founder

## Questions

### Who runs investment decisions at NG Bio?

Co-founders Mohammad Khobreh and Jason Goldstein lead the fund's strategic direction and day-to-day operations, respectively. Khobreh brings the life-sciences family-office track record and manages LP and pharma co-investor relationships; Goldstein handles venture creation and serves as a board member or observer at multiple portfolio companies. Tim Carlton directs therapeutic development and preclinical planning for each venture.

### How does NG Bio source proprietary deal flow?

NG Bio sources through its scientific network rather than competitive syndicate processes. The team's advisors — former senior directors of UCB's new-targets scouting, large-pharma business-development leads, and immunology drug developers — bring early visibility into academic and biotech targets. The firm also collaborates regularly with pharmaceutical companies, sharing deal flow and aligning on growth opportunities before investment.

### Does NG Bio make fund commitments or only direct investments?

NG Bio's model is built around direct venture creation and early-stage equity investments in immunology companies. The firm does not publicly indicate a fund-of-funds program or passive fund-commitment activity. It builds companies from the therapeutic concept stage, works alongside founders on preclinical translation, and then syndicates later rounds.

### What investment stages does NG Bio target?

NG Bio targets early-stage companies—often from ideation and venture creation through preclinical development. The firm's principals have built three companies in-house and led or co-led multiple investment rounds before syndication. The portfolio spans stealth-mode therapeutics alongside active platform and tool companies.

## Related profiles

- [NGB Invest](https://altss.com/profile/ngb-invest)
- [NGC Ventures](https://altss.com/profile/ngc-ventures)

---

Last updated: 2026-08-11T15:07:34.613Z

Canonical page: https://altss.com/profile/ng-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology